الفهرس 
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 232 |  |  |
| | | from | 232 | | |
Abstract
Nephrotic syndrome is a disease characterized by proteinuria,
hypoalbuminemia, hypercholesterolemia and edema.
The nephrotic syndrome is usually involving children between
ages of 2 – 10 years. Primary nephrotic syndrome is more common
in children less than six years of age (80% of cases) while
secondary nephrotic syndrome predominates for patients older
than six years old.
ACEIs and ARBs are increasingly being used for non specific
reduction of nephrotic range proteinuria. These agents reduce
proteinuria by decreasing the transcapillary glomerular hydrostatic
pressure by altering glomerular permeability.
The present study was conducted in Abo El Reish pediatric
hospital and Beni Suef university hospital, aiming to study the role
of ACE-Is and ARBs in reduction of proteinuria.
The study was designed as studied cases and control cases, each
group included 20 nephrotic children cases was collected randomly.
206
ENGLISH SUMMARY
Study group was treated with combination therapy of captopril
and valsartan in addition to prednisolone and control group treated
with captopril and prednisolone only.
Both studied and control cases were subjected to general
examination including blood pressure, clinical examination including
edema and laboratory investigations including serum albumin, serum
cholesterol, albumin in urine and P/C ratio.
We thus initiated this study to evaluate the effect of (ACEIs) plus
(ARBs) in combination therapy on decreasing proteinuria in
children with steroid resistant and steroid dependent nephrotic
syndrome.
The results of our study showed that studied cases that were
treated with combination therapy led to reduction of proteinuria and
decreasing of corticosteroid doses and avoid its side effects as
weight and hypertension. Also this study showed that capsule dosage
form was rapidely absorbed and more bioavailable than tablet dosage
form in treatment of nephrotic children patients.
207